Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 0.85 |
| ▸ | FLT3 | P36888 | 3/20 | 0.85 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.85 |
| ▸ | RPS6KA6 | Q9UK32 | 3/20 | 0.85 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.85 |
| ▸ | CDK9 | P50750 | 2/20 | 0.85 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.84 |
| ▸ | ULK1 | O75385 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19005341 | 0.92 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985439 | 0.92 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL20732780 | 0.91 | TBK1 (0.88) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL19005314 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985621 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985697 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18986018 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985876 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985948 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985264 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |